tirzepatide availability us https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a tirzepatide oral pill availability One

IV therapy best practices covers operational and documentation workflows for injectable drug practices

Early changes may also reflect shifts in water balance

Your transformation is a partnership, and we're committed to your success

These results will determine whether Lilly proceeds with filing

January 2026 The letter and the $250 million facility Facing continued liquidity constraints, and after weeks of unsuccessful negotiations with the lenders, the Company sent a letter dated January 5, 2026 to the Bank Agent and each of the then-existing 16 lenders, focused on the need for immediate liquidity to facilitate an out-of-court sale process and avoid a disorderly liquidation